Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2020-06-26 Capital/Financing Update
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing titled '정정신고(보고)' (Correction Report) regarding a '전환사채권 발행결정' (Decision to Issue Convertible Bonds). It details specific amendments to the terms of a previously announced convertible bond issuance, such as maturity dates, conversion prices, and put/call option details. This falls under the category of capital structure and financing updates, specifically related to debt instruments.
2020-06-26 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing titled '전환사채권 발행결정' (Decision to Issue Convertible Bonds) and includes a '정정신고(보고)' (Correction Report/Amendment). It details specific financial terms such as conversion prices, interest rates, put/call options, and the purpose of the capital raise. This document is a standard corporate filing regarding financing activities and capital structure changes, which falls under the 'Capital/Financing Update' category.
2020-06-25 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing titled '전환사채권 발행결정' (Decision on Issuance of Convertible Bonds) and includes a '정정신고' (Correction Report) header. It details specific terms of a convertible bond issuance, including conversion price adjustments, put/call options, and use of proceeds. This falls under the category of capital structure changes and financing activities, which is classified as 'CAP' (Capital/Financing Update).
2020-06-25 Korean
[기재정정]주요사항보고서(타법인주식및출자증권양도결정)
M&A Activity Classification · 100% confidence The document is a 'Correction Report' (정정신고) regarding a previous 'Major Matter Report' (주요사항보고서) concerning the disposal of shares in another company (타법인 주식 및 출자증권 양도결정). This type of regulatory filing, which details changes to material corporate events like asset disposals or M&A-related transactions, falls under the category of general regulatory announcements when it does not fit into specific categories like M&A (TAR) or Capital Changes (SHA). Given the nature of the filing as a regulatory disclosure to the Korea Exchange/Financial Services Commission, it is classified as a Regulatory Filing (RNS).
2020-06-23 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Lumi Micro) announcing the acquisition of shares in another company (Vivozon). It details the acquisition amount, purpose, board approval, and financial status of the target company. This type of corporate action, specifically the acquisition of shares in another entity, falls under M&A activity (Mergers and Acquisitions) as it represents a strategic investment and expansion of business interests.
2020-06-16 Korean
[기재정정]타법인주식및출자증권처분결정(처분일자 변경 건)
M&A Activity Classification · 100% confidence The document is a regulatory filing from Lumimicro regarding the 'Decision to Dispose of Shares and Securities of Other Corporations'. It specifically details a correction (amendment) to a previously filed disclosure concerning the disposal date of shares in Kumho HT. Since this document relates to a corporate action involving the disposal of assets/investments and does not fit into specific categories like M&A (which usually implies a merger or takeover) or share buybacks (POS), it is best classified as a general regulatory filing (RNS) under the provided schema.
2020-06-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.